PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medtronic Ireland Manufacturing Unlimited Company

USPTO PatentsView assignee record - 43 granted patents across 13 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).

Explore the portfolio See the ranking
43
Total patents granted
13
CPC technology areas
20.2
Avg claims per patent
-
5-year grant velocity

The verdict

According to USPTO PatentsView, Medtronic ranks #7,587 of 50,000 tracked US assignees by granted-patent volume, with 43 patents across 13 technology areas.

#7,587
of 50,000 US assignees by volume
Top 5%
by Innovation Score (57.9/100)
20.2
avg claims per patent

Portfolio overview

Medtronic Ireland Manufacturing Unlimited Company has been granted 43 US utility patents between 2023 and 2025, placing Medtronic Ireland Manufacturing Unlimited Company at #7,587 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.2 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a Foreign Corporation, Medtronic Ireland Manufacturing Unlimited Company is one of the more focused assignees in the PatentsView dataset. By volume, Medtronic sits between Miltenyi Biotec B.v. & Co. KG (43 patents, rank #7,587) and National University Corporation Kyoto Institute OF Technology (43 patents, rank #7,595) - the closest US assignees by grant volume. The composite Innovation Score of 57.9/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2023 through 2025, with 43 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Medtronic Ireland Manufacturing Unlimited Company's 20.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 13 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Medtronic's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Medtronic holds 43 patents at rank #7,591, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Medtronic

By rank, the assignees closest to #7,591 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Medtronic's primary technology class.

Medtronic's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

510152025 202320242025 12
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
Medtronic Ireland Manufacturing Unlimited Company patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 10 23.3%
2024 21 48.8%
2025partial year 12 27.9%

Which technologies does Medtronic Ireland Manufacturing Unlimited Company patent most?

Top 13 of 13 technology areas

Grant record at a glance

Portfolio Volume 43 grants
CPC subclasses 13
Avg. claims / grant 20.2

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#7,587

of 50,000 tracked assignees

Innovation Score

57.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Medtronic Ireland Manufacturing Unlimited Company rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Medtronic Ireland Manufacturing Unlimited Company ranks #7,587 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Medtronic Ireland Manufacturing Unlimited Company hold?
Medtronic Ireland Manufacturing Unlimited Company holds 43 US utility patents granted between 2023 and 2025, spanning 13 technology areas.
What is Medtronic Ireland Manufacturing Unlimited Company's Innovation Score?
Medtronic Ireland Manufacturing Unlimited Company has an Innovation Score of 57.9 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Medtronic Ireland Manufacturing Unlimited Company focus on?
Medtronic Ireland Manufacturing Unlimited Company's top technology area is A61B (DIAGNOSIS; SURGERY; IDENTIFICATION) with 43 patents. Grants appear in 13 CPC subclasses total.
Is Medtronic Ireland Manufacturing Unlimited Company's patent grant rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Medtronic Ireland Manufacturing Unlimited Company.
What does claim depth mean for Medtronic Ireland Manufacturing Unlimited Company's patents?
Medtronic Ireland Manufacturing Unlimited Company's patents average 20.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Medtronic Ireland Manufacturing Unlimited Company patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Medtronic's 43 grants land it in the top 5% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Medtronic ranks #7,587 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61B - see who else leads that technology area. A61B leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.